Medical/Pharmaceuticals
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's firstin vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardio...
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over$100M by issuing 8 million new shares. The new funding will enable Caliway to advance the clinical development of its lead pipeline CBL-514, a sma...
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany, Dec. 16, 2023 /PRNewswire/ -- Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shar...
Wandong Medical's full-line products obtain the MDR certification, facilitating its entry to the European market
BEIJING, Dec. 15, 2023 /PRNewswire/ -- Recently, Wandong's seven major series of products obtained the MDR certificate, following the completion of the first MDR certification for superconducting magnetic resonance. So far, Wandong's full range of X-ray, CT and MRI products have been completed t...
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care
SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests SHENZHEN, China, Dec. 15, 2023 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early ...
BioSURE Pro Protective Nasal Spray from the UK: Block airborne viruses instantly for six hours with a Gentle Lavender Scent
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- The weather was gradually cooling down, which means thatHong Kong is entering the winter influenza season. Recently, there has been a significant increase in Mycoplasma pneumoniae infections, the surveillance data from the Centre for Health Protection (CHP...
Tianlong Solution Facilitates the Prevention and Control of Livestock Diseases
XI'AN, China, Dec. 15, 2023 /PRNewswire/ -- It was recently announced that Tianlong Technology complies with the requirements of Chinese Good Manufacturing Practices for animal drugs. This approval further ensures Tianlong's focus on standardized workflows in the development of animal products. ...
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...
BIOCHEETAH ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH NIPPON KAYAKU FOR VECanDx™ IN JAPAN
SINGAPORE and TOKYO, Dec. 15, 2023 /PRNewswire/ -- BioCheetah Pte. Ltd. (Head Office:Singapore; CEO: Dr. Lee Kian Chung; hereinafter "BioCheetah") and Nippon Kayaku Co., Ltd. (Head Office:Tokyo; President: Mr. Atsuhiro Wakumoto; hereinafter "Nippon Kayaku") announce that the two companies have en...
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...
Expediting R&D Digitization for Life Sciences, ArisGlobal Introduces LifeSphere® NavaX™ - The Next-Generation Cognitive Computing Engine
NavaX will revolutionize the end-to-end Research and Development processes with the latest advanced technologies BOSTON, Dec. 15, 2023 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, has today launched LifeSphere NavaX, a cutting-edge cogni...
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisioning completion by Q2 2024 SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on December 13, 2023, t...
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT
Keynote speaker Peter Marks to Deliver Address Free Early Bird Registration Closing Soon NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dre...
BD to become exclusive global license partner (excluding China) for Bactiguard coated Foley catheters
STOCKHOLM, Dec. 14, 2023 /PRNewswire/ -- Bactiguard Holding AB (publ.) today announces strengthened ties with leading global medical technology company Becton Dickinson & Company (BD), Bactiguard's longest and strongest license collaboration. An interim agreement has been signed granting BD an exc...
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...
The Inaugural Fosun Health Conference on Guangdong-Hong Kong-Macao Healthcare Development Integration Held in Hong Kong to Promote "Three Links" Development
HONG KONG, Dec. 14, 2023 /PRNewswire/ -- The Inaugural Fosun Health Conference onGuangdong-Hong Kong-Macao Healthcare Development Integration was successfully held inHong Kong by Fosun Health on December 12, 2023. With the background of integrating medical services ofGuangdong, Hong Kong and Maca...
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients ...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00